- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Grail's Cancer Screening Test Fails to Deliver
Galleri blood test proves ineffective in large clinical trial, raising questions about unproven cancer screening tools
Mar. 16, 2026 at 1:23pm
Got story updates? Submit your updates here. ›
A 28-year-old patient with a family history of cancer was pressured by their doctor to take Grail's expensive Galleri blood test, which claims to detect cancer early. However, a large clinical trial of over 142,000 people found the test failed to reduce stage 3-4 cancer diagnoses or catch cancer at earlier stages, despite Grail's plans to further analyze the data.
Why it matters
This case highlights concerns about the marketing and adoption of unproven cancer screening tools, especially those that are not covered by insurance and can cost patients hundreds of dollars out-of-pocket. It raises questions about the role of doctors in promoting such tests and the need for more rigorous evidence before making them available to the public.
The details
The patient, who is in their late 20s, has an extensive family history of cancer and was told by their doctor that they should expect to receive a cancer diagnosis at some point. The doctor recommended the Galleri blood test, which costs $949 and is not covered by most insurers. While the patient was initially hesitant, they were persuaded by the doctor's recommendation and Grail's marketing around the test. However, a large clinical trial of the Galleri test found it failed to reduce stage 3-4 cancer diagnoses or catch cancer at earlier stages, despite Grail's plans to further analyze the data.
- The patient's doctor recommended the Galleri test during a routine physical appointment.
- Grail filed for FDA approval of the Galleri test in January 2026.
- Grail revealed the results of the large 142,000-person trial last week, showing the test failed to meet its primary endpoints.
The players
Grail
A company that developed the Galleri blood test, which claims to detect cancer early. Grail is planning to further analyze the data from its large clinical trial.
The patient
A 28-year-old individual with an extensive family history of cancer who was pressured by their doctor to take the Galleri test.
The patient's doctor
A Manhattan-based physician who recommended the Galleri test to the patient, citing their family history of cancer.
What’s next
Grail plans to continue following the patients who have already taken the Galleri test to see if the 'favorable trend' in detecting high-mortality stage 4 cancers becomes stronger. However, the overall failure of the test to meet its primary endpoints raises significant doubts about its clinical utility.
The takeaway
This case highlights the need for more rigorous evidence and transparency around new cancer screening tools before they are aggressively marketed to the public, especially when they come with a high out-of-pocket cost. It also raises questions about the role of doctors in promoting unproven tests and the potential conflicts of interest in the healthcare industry's push for preventative care options.
